Clinical trial
Study on Lixisenatide and Counterregulation to Hypoglycemia
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this study examines whether lixisenatide affects the glucagon response to hypoglycemia.
Category | Value |
---|---|
Study start date | 2013-12-16 |